Related Experiment Video
Updated: May 19, 2026
Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications
Published on: February 28, 2014
KP-CoT-23 (CCDC83) is a novel immunogenic cancer/testis antigen in colon cancer
Myung-Ha Song1, Jin-Mok Ha, Dong-Hoon Shin
1Department of Biochemistry, School of Medicine, Pusan National University, Yangsan‑si, Gyeongsangnam‑do 626-770, Republic of Korea.
Abstract:
Cancer/testis (CT) antigens are considered target molecules for cancer immunotherapy. To identify novel CT antigens, immunoscreening of a testicular cDNA library was performed using serum obtained from a colon cancer patient who was immunized with a new dendritic cell vaccine. We isolated 64 positive cDNA clones comprised of 40 different genes, designated KP-CoT-1 through KP-CoT-40. Three of these putative antigens, including KP-CoT-23 (CCDC83), had testis-specific expression profiles in the Unigene database. RT-PCR analysis showed that the expression of 2 KP-Cot-23 variants was restricted to the testis in normal adult tissues. In addition, KP-CoT-23 variants were frequently expressed in a variety of tumors and cancer cell lines, including colon cancer. A serological western blot assay showed IgG antibodies to the KP-CoT-23 protein in 26 of 37 colon cancer patients and in 4 of 21 healthy patients. These data suggest that KP-CoT-23 is a novel CT antigen that may be useful for the diagnosis and immunotherapy of cancer.
Insights
Researchers identified KP-CoT-23 (CCDC83) as a novel cancer/testis (CT) antigen. This antigen is expressed in tumors and elicits an immune response in colon cancer patients, suggesting its potential for cancer diagnosis and immunotherapy.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Cancer/testis (CT) antigens are crucial targets for cancer immunotherapy.
- Identifying novel CT antigens is essential for developing new cancer treatments.
Purpose of the Study:
- To identify and characterize novel cancer/testis antigens.
- To evaluate KP-CoT-23 (CCDC83) as a potential diagnostic and therapeutic target for cancer.
Main Methods:
- Immunoscreening of a testicular cDNA library using patient serum.
- RT-PCR analysis to determine tissue-specific expression.
- Serological western blot assay to detect patient antibodies.
Main Results:
- Isolated 40 novel putative CT antigens, including KP-CoT-23 (CCDC83).
- KP-CoT-23 expression was restricted to the testis in normal tissues.
- KP-CoT-23 variants were frequently expressed in various tumors, including colon cancer.
- IgG antibodies against KP-CoT-23 were detected in a significant proportion of colon cancer patients.
Conclusions:
- KP-CoT-23 (CCDC83) is a novel cancer/testis antigen.
- KP-CoT-23 shows promise for cancer diagnosis and immunotherapy, particularly for colon cancer.
More Related Videos
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019